TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37098852

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 268
Study: 37099132

Group type: EXPERIMENTAL
Intervention: CLDN18.2 functional diagnostic PET imaging
Number of subjects: 0
Study: 37099252

Group type: EXPERIMENTAL
Intervention: FundoRingOAGB (f-OAGB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard OAGB (s-OAGB)
Number of subjects: 100
Study: 37099280

Group type: EXPERIMENTAL
Intervention: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Cytoreduction alone
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes) in pT4 subgroup
Number of subjects: 184

Group type: COMPARATOR
Intervention: Cytoreduction alone in pT4 subgroup
Number of subjects: 184
Study: 37099283

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 37099295

Group type: EXPERIMENTAL
Intervention: IM tixagevimab-cilgavimab (300 mg IV or 600 mg IM)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: IV tixagevimab-cilgavimab (300 mg IV)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 37099298

Group type: EXPERIMENTAL
Intervention: Repeated low-level red light (RLRL) therapy, twice per day, 5 days per week, each session lasting 3 minutes.
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: RLRL therapy (for those without treatment interruption due to COVID-19).
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: RLRL therapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 139
Study: 37099299

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 2247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2247
Study: 37099341

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccine
Number of subjects: 3988

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 3988
Study: 37099363

Group type: EXPERIMENTAL
Intervention: Digital messaging therapy
Number of subjects: 24
Study: 37099364

Group type: EXPERIMENTAL
Intervention: Social network-based HIV self-test approach
Number of subjects: 463
Study: 37099367

Group type: EXPERIMENTAL
Intervention: App-based case management service
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 344
Study: 37099376

Group type: EXPERIMENTAL
Intervention: TreadWill (unguided computerized cognitive behavioral therapy)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Full-featured version of TreadWill
Number of subjects: 598
Study: 37099498

Group type: EXPERIMENTAL
Intervention: Baseline Neck Disability Index (NDI) scores
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Baseline Numeric Pain Rating Scale (NPRS) scores
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Interaction term of sex x z-NPRS
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Baseline NDI in males
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Baseline NPRS in females
Number of subjects: 97
Study: 37099511

Group type: EXPERIMENTAL
Intervention: North Star Ambulatory Assessment (NSAA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient and parent perception using participant-tailored questionnaires
Number of subjects: 0
Study: 37099652

Group type: EXPERIMENTAL
Intervention: Parents Taking Action (PTA) intervention
Number of subjects: 15
Study: 37099733

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Biomarkers (PD-L1 CPS, CD8, sTIL, TMB, etc.)
Number of subjects: 254
Study: 37099736

Group type: EXPERIMENTAL
Intervention: Adagrasib (600 mg orally twice daily)
Number of subjects: 64
Study: 37099777

Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS) and Magnetic Resonance Imaging (MRI)
Number of subjects: 102
Study: 37099968

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2-3 mg/day
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 0.5-3 mg/day
Number of subjects: 579

Group type: COMPARATOR
Intervention: ADT + placebo
Number of subjects: 579
Study: 37099983

Group type: EXPERIMENTAL
Intervention: Ospemifene
Number of subjects: 752

Group type: COMPARATOR
Intervention: Vaginal moisturizers
Number of subjects: 752

Group type: COMPARATOR
Intervention: Local estrogen therapy
Number of subjects: 752
Study: 37100060

Group type: EXPERIMENTAL
Intervention: ADAR2 genetic ablation from vascular endothelial cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADAR2 presence in endothelium
Number of subjects: 0
Study: 37100160

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2)
Number of subjects: 75
Study: 37100187

Group type: EXPERIMENTAL
Intervention: Atomoxetine 80 mg daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 37100205

Group type: EXPERIMENTAL
Intervention: Machine learning-based immune phenotyping (ML-derived immune phenotypes)
Number of subjects: 934

Group type: EXPERIMENTAL
Intervention: Concurrent KEAP1 and STK11 mutations in lung adenocarcinoma (LUAD)
Number of subjects: 934
Study: 37100202

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 2
Study: 37100349

Group type: EXPERIMENTAL
Intervention: 250-mg 17-hydroxyprogesterone caproate
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 500-mg 17-hydroxyprogesterone caproate
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both doses of 17-hydroxyprogesterone caproate
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Postenrollment cerclage
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Initial cervical length
Number of subjects: 159
Study: 37100424

Group type: EXPERIMENTAL
Intervention: Early-onset pectus excavatum (PE)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Referral for genetic counseling
Number of subjects: 18
Study: 37100486

Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 4617

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 4617
Study: 37100536

Group type: EXPERIMENTAL
Intervention: Heart failure hospitalization (HHF) or HF death
Number of subjects: 12124

Group type: COMPARATOR
Intervention: Fatal and nonfatal stroke/systemic embolic events (SEE)
Number of subjects: 12124

Group type: COMPARATOR
Intervention: Major bleeding (MB)
Number of subjects: 12124

Group type: EXPERIMENTAL
Intervention: Heart failure hospitalization (HHF) or HF death in HFrEF vs HFpEF
Number of subjects: 12124

Group type: EXPERIMENTAL
Intervention: Mortality after HHF
Number of subjects: 12124

Group type: COMPARATOR
Intervention: Mortality after stroke/SEE
Number of subjects: 12124

Group type: COMPARATOR
Intervention: Mortality after MB
Number of subjects: 12124
Study: 37100687

Group type: EXPERIMENTAL
Intervention: Iodine intake <150 μg/d
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Iodine intake >550 μg/d
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Daily iodine intake at zero balance
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Iodine intake at zero balance with adequate iodine nutrition
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Calculated recommended nutrient intake (RNI)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Iodine intakes <150 μg/d and >550 μg/d
Number of subjects: 93
Study: 37100705

Group type: COMPARATOR
Intervention: 2-week placebo modulator study
Number of subjects: 1791

Group type: COMPARATOR
Intervention: 6-month placebo modulator study
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: 2-week active-comparator modulator study
Number of subjects: 1791

Group type: EXPERIMENTAL
Intervention: 6-month active-comparator modulator study
Number of subjects: 1791

Group type: COMPARATOR
Intervention: 2-week placebo inhaled antimicrobial study
Number of subjects: 1791

Group type: COMPARATOR
Intervention: 6-month placebo inhaled antimicrobial study
Number of subjects: 1791
Study: 37100821

Group type: EXPERIMENTAL
Intervention: Men with HFmrEF
Number of subjects: 1691
Study: 37100869

Group type: EXPERIMENTAL
Intervention: Imagery-competing task intervention (immediate access)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Delayed access to the imagery-competing task intervention (after 4 weeks)
Number of subjects: 75
Study: 37100891

Group type: EXPERIMENTAL
Intervention: Longer daily eating window
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Shorter time from midsleep point to first food intake
Number of subjects: 118

Group type: COMPARATOR
Intervention: Meal timing
Number of subjects: 118
Study: 37101143

Group type: EXPERIMENTAL
Intervention: Smaller meal portions
Number of subjects: 96

Group type: COMPARATOR
Intervention: Larger meal portions
Number of subjects: 96
Study: 37101228

Group type: EXPERIMENTAL
Intervention: Active acupuncture regimen (15 sessions combining needling into body acupoints and acupressure on auricular acupoints)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Active acupuncture regimen
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sham acupuncture control
Number of subjects: 138
Study: 37101251

Group type: EXPERIMENTAL
Intervention: Stimulant use (primarily meth)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Stimulant use
Number of subjects: 25
Study: 37101272

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNC-O)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 141
Study: 37101521

Group type: EXPERIMENTAL
Intervention: Monthly fremanezumab
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Quarterly fremanezumab
Number of subjects: 588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study: 37101768

Group type: EXPERIMENTAL
Intervention: Erdafitinib (8 mg/d continuous in 28-d cycles, uptitration to 9 mg/d if serum phosphate <5.5 mg/dl)
Number of subjects: 101
Study: 37101774

Group type: EXPERIMENTAL
Intervention: Culture-based prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empirical ciprofloxacin prophylaxis
Number of subjects: 0
Study: 37101983

Group type: EXPERIMENTAL
Intervention: Vaginal dexamethasone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 37102010

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (non-lasered T2DM patients)
Number of subjects: 40
Study: 37102392

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri and omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) supplementation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 120
Study: 37102399

Group type: EXPERIMENTAL
Intervention: Experimental infection with ETEC
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lymphocyte response analysis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CD56dim CD16 lymphocyte response
Number of subjects: 9
Study: 37102600

Group type: EXPERIMENTAL
Intervention: Prototype investigational device
Number of subjects: 29
Study: 37102598

Group type: EXPERIMENTAL
Intervention: KCd (weekly carfilzomib 70 mg/m2, cyclophosphamide, and dexamethasone)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Kd (carfilzomib and dexamethasone)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: KCd (in lenalidomide-refractory population)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Kd (in lenalidomide-refractory population)
Number of subjects: 197

Group type: COMPARATOR
Intervention: KCd and Kd (overall response rate)
Number of subjects: 197

Group type: COMPARATOR
Intervention: KCd and Kd (safety profile)
Number of subjects: 197
Study: 37102974

Group type: EXPERIMENTAL
Intervention: Combination diuretic therapy (loop diuretics with an add-on agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loop diuretics
Number of subjects: 0
Study: 37103493

Group type: EXPERIMENTAL
Intervention: StressProffen-CBI (Cognitive Behavioral Therapy Intervention)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: StressProffen-MBI (Mindfulness-Based Intervention)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: StressProffen-CBI
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: StressProffen-MBI
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: StressProffen-CBI and StressProffen-MBI
Number of subjects: 430
Study: 37103532

Group type: EXPERIMENTAL
Intervention: Oral GnRH antagonists (elagolix 300 mg twice daily with estradiol 1 mg and norethindrone 0.5 mg; relugolix 40 mg once daily with estradiol 1 mg and norethindrone 0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral GnRH antagonists with menopausal replacement-level steroid hormones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linzagolix (under investigation)
Number of subjects: 0
Study: 37103536

Group type: EXPERIMENTAL
Intervention: Patient navigation
Number of subjects: 102
Study: 37103585

Group type: EXPERIMENTAL
Intervention: Minimally invasive endoscopy-guided surgery within 8 h after symptom onset
Number of subjects: 40
Study: 37103592

Group type: EXPERIMENTAL
Intervention: Physical exercise and dietary therapy (PED-t)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PED-t and CBT (combined analysis)
Number of subjects: 0
Study: 37103597

Group type: EXPERIMENTAL
Intervention: Outcomes4Me mobile app
Number of subjects: 107
Study: 37103656

Group type: EXPERIMENTAL
Intervention: Mild malnutrition
Number of subjects: 12652

Group type: EXPERIMENTAL
Intervention: Moderate malnutrition
Number of subjects: 12652

Group type: EXPERIMENTAL
Intervention: Severe malnutrition
Number of subjects: 12652

Group type: COMPARATOR
Intervention: Absent malnutrition
Number of subjects: 12652
Study: 37103658

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 37103682

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) 5 times a week for 5 weeks, consisting of high-intensity training with sets increasing from 5 to 9 over the training period.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) 5 times a week for 5 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rehabilitation program activities including aerobic exercise, resistance training, and educational class.
Number of subjects: 40
Study: 37103756

Group type: EXPERIMENTAL
Intervention: Spinal multimodal MRI
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clinical prognostic factors
Number of subjects: 41
Study: 37103915

Group type: EXPERIMENTAL
Intervention: Lumateperone, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 37103935

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 37103991

Group type: EXPERIMENTAL
Intervention: 6-month behavioral weight loss intervention delivered via Facebook
Number of subjects: 62

Group type: COMPARATOR
Intervention: 6-month behavioral weight loss intervention delivered via in-person groups
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Sustained participation defined by intervention meeting attendance or visible engagement in the Facebook group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Percent weight loss at 6 and 12 months
Number of subjects: 62
Study: 37104214

Group type: EXPERIMENTAL
Intervention: Proton-Pump Inhibitors (PPIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37104280

Group type: EXPERIMENTAL
Intervention: Parent Web intervention (internet-based parent training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (matched sample of adolescents with no prior experience of PATHS)
Number of subjects: 0
Study: 37104305

Group type: EXPERIMENTAL
Intervention: Permethrin-treated baby wrap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-treated wrap (placebo)
Number of subjects: 0
Study: 37104481

Group type: EXPERIMENTAL
Intervention: FITC-sinistrin clearance during CRRT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Transdermal measurement of FITC-sinistrin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 5
Study: 37104641

Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 113
Study: 37104746

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant pembrolizumab
Number of subjects: 0
Study: 37104748

Group type: COMPARATOR
Intervention: Dose-escalated radiotherapy (RT) alone
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Dose-escalated radiotherapy (RT) with short-term androgen deprivation (STAD)
Number of subjects: 1492
Study: 37104758

Group type: EXPERIMENTAL
Intervention: Combination therapy of margetuximab and pembrolizumab
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ctDNA analysis
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Current ERBB2 status
Number of subjects: 86
Study: 37104870

Group type: COMPARATOR
Intervention: Paclitaxel (arm A)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cixutumumab (arm B)
Number of subjects: 87
Study: 37104871

Group type: EXPERIMENTAL
Intervention: GRACE intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 71
Study: 37104931

Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 0
Study: 37104944

Group type: EXPERIMENTAL
Intervention: Highest quartile (Q4) of FT3/FT4 ratio
Number of subjects: 3648
Study: 37104979

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 2423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2423

Group type: EXPERIMENTAL
Intervention: NAFLD-LFS
Number of subjects: 2423

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 2423
Study: 37105060

Group type: EXPERIMENTAL
Intervention: Laparo-endoscopic single-site surgery (LESS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 107
Study: 37105162

Group type: EXPERIMENTAL
Intervention: Magnetoencephalographic neurofeedback training
Number of subjects: 0
Study: 37105210

Group type: EXPERIMENTAL
Intervention: Allogeneic haematopoietic stem cell transplantation (HSCT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Non-allogeneic HSCT therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 99
Study: 37105234

Group type: EXPERIMENTAL
Intervention: Serum AMH measurement using an AMH automated assay
Number of subjects: 4556

Group type: EXPERIMENTAL
Intervention: Optimal cut-off for PCOS diagnosis
Number of subjects: 4556

Group type: EXPERIMENTAL
Intervention: Age, ethnicity, obesity, PCOS, and endometrioma cystectomy history
Number of subjects: 4556
Study: 37105265

Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 476

Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 476
Study: 37105304

Group type: EXPERIMENTAL
Intervention: SBRT plus EGFR-TKI
Number of subjects: 62

Group type: COMPARATOR
Intervention: EGFR-TKI alone
Number of subjects: 62
Study: 37105318

Group type: EXPERIMENTAL
Intervention: Behavior change technique (BCT) intervention
Number of subjects: 42
Study: 37105430

Group type: EXPERIMENTAL
Intervention: Remotely delivered exercise-based cardiac rehabilitation (EBCR)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Center-based exercise-based cardiac rehabilitation (EBCR)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Remote EBCR
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control (center-based EBCR)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Follow-up of major adverse cardiovascular events
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Safety monitoring of serious adverse events
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 1500
Study: 37105508

Group type: COMPARATOR
Intervention: ACT
Number of subjects: 234

Group type: COMPARATOR
Intervention: BATD
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: TAU
Number of subjects: 234
Study: 37105511

Group type: EXPERIMENTAL
Intervention: Extensive repair
Number of subjects: 5510

Group type: COMPARATOR
Intervention: Proximal repair
Number of subjects: 5510
Study: 37105689

Group type: EXPERIMENTAL
Intervention: Immunotherapy (specific types not detailed)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Data extraction from electronic patient files and historical databases
Number of subjects: 1800
Study: 37105693

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) with very high neutralising antibody titre administered within 7 days of symptom onset plus standard of care
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 1020
Study: 37105694

Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG), brainstem evoked potentials, transcranial doppler, bedside haemodynamic monitors
Number of subjects: 90
Study: 37105705

Group type: EXPERIMENTAL
Intervention: TEVAR with carbon dioxide flushing (TEVAR-CO)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TEVAR with saline flushing (control)
Number of subjects: 120
Study: 37105885

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 2
Study: 37105892

Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 1184

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1184

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib and RV1
Number of subjects: 1184
Study: 37106078

Group type: EXPERIMENTAL
Intervention: Centre-based childcare full-time (40 h/week)
Number of subjects: 3503

Group type: EXPERIMENTAL
Intervention: Centre-based childcare full-time (40 h/week) for families with income < $50,000 CDN
Number of subjects: 3503
Study: 37106099

Group type: EXPERIMENTAL
Intervention: Peripheral plasma concentrations of succinate obtained during coronary revascularization
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Peripheral plasma concentrations of other metabolites
Number of subjects: 111